SV Life Sciences
Venture capitalBoston · 10 people tracked
Also known as SV Life Sciences CF · SV Life Sciences Strategic Partners
Find your way into SV Life Sciences
2 people in our graph share verified history with the SV Life Sciences team — schools, employers, funds. One of them is your warm intro.
Fund manager profile
SV Life Sciences is a venture fund manager based in Boston. SEC filings show 3 venture funds on record, most recently SV Life Sciences Fund IV CF, L.P. ($421.4M offering) filed March 2022.
Source: SEC EDGAR Form D filings. Firm website data not yet available.
Team · 10 people
from public directoriesWhat they invest in
from 11 of 12 portfolio companiesHealthtech ×7Biotech ×6AI & Machine Learning ×3Medical Devices ×3Deep Tech ×2Hardware ×1Robotics ×1
HQs:United States×11
Investments · 12 tracked
founders shown can be your intro pathBy year:2025 · 12018 · 12017 · 12016 · 12014 · 12012 · 16 dated
American Well operates a digital healthcare platform that connects patients, physicians, and healthcare professionals to provide remote clinical services, earning revenue through arrangements with healthcare organizations and clients who use its technology to deliver telehealth and related services.
HealthtechBoston, US
Ido Schoenberg(Executive Officer, Director)inRoy Schoenberg(Executive Officer, Director)inJames Malone(Executive Officer)inBradford F. Gay(Executive Officer)Phyllis Gotlib(President, International)inMark Hirschhorn(Executive Vice President, Chief Financial Officer and Chief Operating Officer)in
Co-investorsHanaco Venture CapitalMartin VenturesSV Health Investors
Cerevance develops precision novel therapeutics for central nervous system disorders, particularly neurodegenerative diseases, using its proprietary NETSseq platform and machine learning to identify targets from an extensive collection of human brain tissue samples.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesBoston, US
Craig Thompson(Chief Executive Officer)inSagar Vaidya(Chief Medical Officer)inCarrie Ann Cook(Chief Business Officer)Mark Carlton(Chief Scientific Officer)inOttavio V. Vitolo(Chief Medical Officer)in
Co-investorsForesite CapitalGV (Google Ventures)Dementia Discovery FundDementia DiscoveryLightstone VenturesSV Health Investors+2 more
HealthtechSunnyvale, US
Thomas Afzal(Executive Officer, Director)
BoardPeter van der Velden(Director)inDan Galles(Director)Mark Brooks(Director)Richard Ferrari(Director)
Board seatDavid Milne· per SEC Form D · $1.6M raise · filed Nov 2016
Co-investorsHLM Venture PartnersLumira VenturesSV Health Investors
Asensus Surgical (formerly TransEnterix) develops robotic-assisted surgical systems and augmented intelligence technology, including reusable instruments, to give surgeons real-time information during procedures.
AI & Machine LearningHealthtechMedical DevicesRoboticsMorrisville, US
Anthony Fernando(Executive Officer)inTodd M. Pope(Executive Officer, Director)inJoseph P Slattery(Executive Officer)inJames J. Martin(Executive Officer)Charles J. Filipi(Executive Officer, Director)Jeffrey G. Spragens(Executive Officer, Director)
Board seatDavid B Milne· per SEC Form D · $950K raise · filed Sep 2017
Co-investorsAisling CapitalSV Health InvestorsQuaker BioVentures
BiotechIrvine, US
Alan Waterhouse(President and Chief Operating Officer)Jason Tester(Chief Financial Officer and Secretary)James V. Mazzo(President, Chief Executive Officer and Chairman of the Board)
BoardArjun Arora(Director)Richard L. Lindstrom, M.D.(Director)William J. Link(Director)
Co-investorsEvidity Health CapitalFlying L PartnersHEALTHCARE ROYALTY PARTNERSVersant Venture AIV HoldingsVersant Ventures
Adimab develops proprietary platforms for antibody and protein therapeutic discovery, engineering fully-functional immunoglobulins in a controllable in vitro eukaryotic system.
AI & Machine LearningBiotechDeep TechVermont, US
Co-investorsGrandBanks CapitalLaunchCapitalLux CapitalPremji InvestSV Health InvestorsMithril Capital Management+1 more
Advanced ManufacturingBiotechHardwareLebanon, US
Tillman Gerngross(Director)Errik Anderson(Director)inWarren Kett(Executive Officer)Jon Sheller(Executive Officer)Kevin Issett(Executive Officer, Director)Kevin Isett(Executive Officer, Director)
Co-investorsOrbiMedSV Health InvestorsMithril Capital ManagementSands Capital Ventures
BiotechNew York, US
David Guyer(Executive Officer, Director)Glenn Sblendorio(Executive Officer, Director)Mike AtiehinDavid Redlick(Director)Keith Westby(Executive Officer)David Carroll(Executive Officer)
Co-investorsSofinnova VenturesSV Health InvestorsClarus
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.
BiotechHealthtech
Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin
Co-investorsAdjuvant CapitalF-Prime CapitalJeito CapitalLongwood FundSR One Capital ManagementSV Health Investors+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
1 IPOs · 1 acquisitionsAmerican WellNYSE: AMWLAvitideacq. by Repligen
Portfolio news
latest coverage across their companiesAmerican Well · in.investing.com · Aug 13, 2026
Cerevance · citybiz.co · May 12, 2026
Karus · finance.yahoo.com · Jan 14, 2026
Fund performance · per public LP disclosures
as of Jun 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| SV Life Sciences Fund VI, L.P.LPs: New Mexico Educational Retirement Board | 2015 | — | 14.0% | 1.58x | 1.22x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| American Well | — | $27.50 | Jan 2021 | $25M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Frequently asked questions
- How many investments has SV Life Sciences made?
- SV Life Sciences has 12 tracked investments, 2 of which have exited, including 1 dated in the last 24 months.
- Where is SV Life Sciences located?
- SV Life Sciences is headquartered in Boston, US.